|
Enveric Biosciences, a biotechnology company dedicated to the development of novel neuroplastogens for the treatment of neuropsychiatric disorders, announces the expansion of patent protection for a broad range of molecules in its EVM301 portfolio through the issuance of five additional US patents and the recent allowance of three more patent applications by the United States Patent and Trademark Office.
The US Patent Nos. 11,845,727; 11,858,895; 11,891,359; 11,998,557 and 12,128,058 join four other patents previously announced, bringing the total to nine issued US patents covering the EVM301 portfolio and its drug candidate library. Enveric’s Psybrary is a proprietary catalogue of over 1,000 tryptamine derivative molecules that incorporates receptor engagement and functional data to correlate structure with biological activity.
“The increasing depth and breadth of the EVM301 portfolio of molecules with strong intellectual property backing expands the value-capture opportunities available to Enveric,” said Dr. Joseph Tucker, CEO of Enveric. “The EVM301 portfolio extends across a broad range of tryptamine derivative molecules including, but not limited to, carboxylated, aminated, prenylated, glycosylated, nitrilated, and halogenated derivative molecules, and combinations of two or more of these functional motifs, in the form of multi-substituent tryptamine derivatives.”
Enveric’s drug discovery engine has also uncovered molecules demonstrating enhanced preference for 5-HT2C receptors. “Included in our portfolio are several molecules, protected by issued patent claims, with potential as antiepileptic and anti-obesity drug candidates, which have demonstrated enhanced binding preference for the 5-HT2C receptor relative to other serotonergic, dopaminergic, and adrenergic receptor targets,” reported Dr. Tucker.
The lead candidate derived from the EVM301 Series of compounds, EB-003, which targets major undertreated mental health indications including treatment-resistant depression and anxiety, is currently in preclinical development to support filing an Investigational New Drug (IND) application in 2025. The favourable safety profile of EB-003 is supported by receptor engagement data with key serotonergic targets that suggest the ability to promote clinically important neuroplasticity without inducing hallucinations, a significant safety concern limiting the potential to reach patients.
Enveric Biosciences is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders.
|